Selected article for: "acute syndrome and low molecular"
Author: Stasi, Cristina; Fallani, Silvia; Voller, Fabio; Silvestri, Caterina
Title: Treatment for COVID-19: An overview
  • Cord-id: vrz781z4
  • Document date: 2020_12_15
    • ID: vrz781z4
    Snippet: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a characteristic hyperinflammatory response, vascular damage, microangiopathy, angiogenesis and widespread thrombosis. Four stages of COVID-19 have been identified: the first stage is characterised by upper respiratory tract infection; the second by the onset of dyspnoea and pneumonia; the third by a worsening clinical scenario dominated by a cytokine
    Document: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a characteristic hyperinflammatory response, vascular damage, microangiopathy, angiogenesis and widespread thrombosis. Four stages of COVID-19 have been identified: the first stage is characterised by upper respiratory tract infection; the second by the onset of dyspnoea and pneumonia; the third by a worsening clinical scenario dominated by a cytokine storm and the consequent hyperinflammatory state; and the fourth by death or recovery. Currently, no treatment can act specifically against the SARS-CoV-2 infection. Based on the pathological features and different clinical phases of COVID-19, particularly in patients with moderate to severe COVID-19, the classes of drugs used are antiviral agents, inflammation inhibitors/antirheumatic drugs, low molecular weight heparins, plasma, and hyperimmune immunoglobulins. During this emergency period of the COVID-19 outbreak, clinical researchers are using and testing a variety of possible treatments. Based on these premises, this review aims to discuss the most updated pharmacological treatments to effectively act against the SARS-CoV-2 infection and support researchers and clinicians in relation to any current and future developments in curing COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • access treatment and administration time: 1
    • acute ards respiratory distress syndrome and add treatment: 1, 2
    • acute ards respiratory distress syndrome and additional intervention: 1, 2
    • acute ards respiratory distress syndrome and administer dose: 1
    • acute ards respiratory distress syndrome and administration dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and administration efficacy: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and administration time: 1, 2, 3, 4, 5, 6
    • add treatment and administration efficacy: 1